Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ blood
Carcinoma, Hepatocellular
/ blood
Case-Control Studies
Chemoembolization, Therapeutic
/ statistics & numerical data
Female
Healthy Volunteers
Humans
Intramolecular Oxidoreductases
/ blood
Kaplan-Meier Estimate
Liver Neoplasms
/ blood
Macrophage Migration-Inhibitory Factors
/ blood
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Assessment
/ methods
Treatment Outcome
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
16
02
2021
received:
23
12
2020
accepted:
17
02
2021
pubmed:
1
4
2021
medline:
16
2
2022
entrez:
31
3
2021
Statut:
ppublish
Résumé
Transarterial chemoembolization (TACE) is a therapeutic option for patients with intermediate-stage hepatocellular carcinoma (HCC) or metastatic liver cancers. Identifying those patients who particularly benefit from TACE remains challenging. Macrophage migration inhibitory factor (MIF) represents is an inflammatory protein described in patients with liver cancer, but no data on its prognostic relevance in patients undergoing TACE exist. Here, we evaluate MIF serum concentrations as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies. MIF serum concentrations were measured by multiplex immunoassay in 50 patients (HCC: n = 39, liver metastases: n = 11) before and 1 day after TACE as well as in 51 healthy controls. Serum concentrations of MIF did not differ between patients and healthy controls. Interestingly, in the subgroup of patients with larger tumor size, significantly more patients had increased MIF concentrations. Patients with an objective tumor response to TACE therapy showed comparable concentrations of serum MIF compared to patients who did not respond. MIF concentrations at day 1 after TACE were significantly higher compared to baseline concentrations. Importantly, baseline MIF concentrations above the optimal cutoff value (0.625 ng/ml) turned out as a significant and independent prognostic marker for a reduced overall survival (OS) following TACE: patients with elevated MIF concentrations showed a significantly reduced median OS of only 719 days compared to patients below the cutoff value (median OS: 1430 days, p = 0.021). Baseline MIF serum concentrations are associated with tumor size of intrahepatic malignancies and predict outcome of patients with liver cancer receiving TACE.
Identifiants
pubmed: 33787014
doi: 10.1111/cts.13033
pmc: PMC8504849
doi:
Substances chimiques
Biomarkers, Tumor
0
Macrophage Migration-Inhibitory Factors
0
Intramolecular Oxidoreductases
EC 5.3.-
MIF protein, human
EC 5.3.2.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1853-1863Informations de copyright
© 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Références
Semin Intervent Radiol. 2017 Jun;34(2):145-166
pubmed: 28579683
Abdom Radiol (NY). 2018 Jan;43(1):13-25
pubmed: 28647765
Oncol Lett. 2016 Oct;12(4):2247-2253
pubmed: 27698786
Cancer Lett. 2001 Oct 10;171(2):125-32
pubmed: 11520595
BJS Open. 2019 Apr 29;3(4):500-508
pubmed: 31388642
Immunity. 2007 Mar;26(3):281-5
pubmed: 17376392
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Hepatology. 2015 Jan;61(1):191-9
pubmed: 25142309
Hepatology. 2018 Jan;67(1):422-435
pubmed: 28881497
J Hepatol. 2017 Nov;67(5):1018-1025
pubmed: 28647568
Expert Opin Pharmacother. 2011 May;12(7):1057-73
pubmed: 21470073
Anticancer Res. 2020 Jan;40(1):1-7
pubmed: 31892548
Int J Cancer. 2011 Nov 15;129(10):2463-72
pubmed: 21213214
Langenbecks Arch Surg. 2015 Aug;400(6):641-59
pubmed: 26088872
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Hepatocell Carcinoma. 2017 Jul 27;4:105-110
pubmed: 28795053
World J Clin Oncol. 2017 Jun 10;8(3):190-202
pubmed: 28638789
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Surg Clin North Am. 2020 Jun;100(3):551-563
pubmed: 32402300
Oncol Rep. 2014 Mar;31(3):1199-204
pubmed: 24366206
Hepatology. 2014 Feb;59(2):580-91
pubmed: 23913513
Cancer. 2005 Feb 1;103(3):588-98
pubmed: 15612021
Science. 1966 Jul 1;153(3731):80-2
pubmed: 5938421
Clin Transl Sci. 2021 Sep;14(5):1853-1863
pubmed: 33787014
J Hepatol. 2017 Oct;67(4):749-757
pubmed: 28668580
Front Biosci (Landmark Ed). 2017 Mar 1;22:1365-1378
pubmed: 28199208
Carcinogenesis. 2013 Dec;34(12):2891-9
pubmed: 23825153
Hepatology. 2013 Jun;57(6):2261-73
pubmed: 23316013